The advent of the human immunodeficiency virus infection and the increasing prevalence of compromised individuals in the community due to modern therapeutic advances have resulted in a resurgence of opportunistic infections, including oral candidoses. One form of the latter presents classically as a white lesion of "thrush" and is usually easily diagnosed and cured. Nonetheless, a minority of these lesions appears in new guises such as erythematous candidosis, thereby confounding the unwary clinician and complicating its management. Despite the availability of several effective antimycotics for the treatment of oral candidoses, failure of therapy is not uncommon due to the unique environment of the oral cavity, where the flushing effect of saliva and the cleansing action of the oral musculature tend to reduce the drug concentration to sub-therapeutic levels. This problem has been partly circumvented by the introduction of the triazole agents, which initially appeared to be highly effective. However, an alarming increase of organisms resistant to the triazoles has been reported recently. In this review, an overview of clinical manifestations of oral candidoses and recent advances in antimycotic therapy is given, together with newer concepts, such as the post-antifungal effect (PAFE) and its possible therapeutic implications.
References
1.
Abu-El Teen K., Ghannum M., Stretton RJ (1989). Effects of sub-inhibitory concentrations of antifungal agents on adherence of Candida spp. to buccal epithelial cells in vitro. Mycoses32:551-562.
2.
Aleck KA, Bartley DL (1997). Multiple malformation syndrome following fluconazole use in pregnancy; report of an additional patient. Am J Med Genet72:253-256.
3.
Anaissie EJ, Karyotakis NC, Hachem R., Dignani MC, Rex JH, Paetznick V. (1994). Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis170:384-389.
4.
Arendorf TM, Bredekamp B., Cloete CAC, Sauer G. (1998). Oral manifestations of HIV infection in 600 South African patients. J Oral Pathol Med27:176-179.
5.
Arikan A., Kulak Y., Kadir T. (1995). Comparison of different treatment methods for localized and generalized simple denture stomatitis. J Oral Rehabil22:365-369.
6.
Ariyaratnam S., Thakker NS, Sloan P., Thornhill MH (1997). Drug points: potentiation of warfarin anticoagulant activity by miconazole oral gel. Br Med J314:349.
7.
Arranz-Caso JA, Lopez-Pizarro VM, Gomez-Herruz P., Garcia-Altozano J., Martinez-Martinez J. (1996). C. albicans osteomyelitis of the zygomatic bone. A distinctive case with a possible peculiar mechanism of infection and therapeutic failure with fluconazole. Diagn Microbiol Infect Dis24:161-164.
8.
Audus K., Tavalikoli-Saberi M., Zheng H., Boyce E. (1992). Chlorhexidine effects on membrane lipid domains of human buccal epithelial cells. J Dent Res71:1298-1303.
9.
Axell T., Samaranayake LP, Reichart PA, Olsen I. (1997). A proposal for reclassification of oral candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod84:111-112.
Banting DW, Greenhorn PA, McMinn JG (1995). Effectiveness of a topical antifungal regimen for the treatment of oral candidiasis in older, chronically ill, institutionalized, adults. J Can Dent Assoc61:199-200, 203-205.
12.
Barchiesi F., Colombo AL, McGough DA, Fothergill AW, Rinaldi MG (1994). In vitro activity of itraconazole against fluconazole-susceptible and resistant C. albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother38:1530-1533.
13.
Barchiesi F., Hollis RJ, Del Poeta M., McGough DA, Scalise G., Rinaldi MG, et al. (1995). Transmission of fluconazole-resistant C. albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed field gel electrophoresis. Clin Infect Dis21:561-564.
14.
Barchiesi F., Najvar LK, Luther MF, Scalise G., Rinaldi MG, Graybill JR (1996). Variation in fluconazole efficacy for C. albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model. Antimicrob Agent Chemother40:1317-1320.
15.
Barkvoll P., Attramadal A. (1989). Effect of nystatin and chlorhexidine gluconate on C. albicans. Oral Surg Oral Med Oral Pathol67:279-281.
16.
Begg MD, Panageas KS, Mitchell-Lewis D., Bucklan RS, Phelan JA, Lamster IB (1996). Oral lesions as markers of severe immunosuppression in HIV-infected homosexual men and injection drug users. Oral Surg Oral Med Oral Pathol Oral Radiol Endod82:276-283.
17.
Bissell V., Felix DH, Wray D. ( 1993). Comparative trial of fluconazole and amphotericin B in the treatment of denture stomatitis. Oral Surg Oral Med Oral Pathol76:35-39.
18.
Blatchford NR (1990). Treatment of oral candidosis with itraconazole: a review. I Am Acad Dermatol23:565-567.
19.
Boerlin P., Addo M., Durussel C., Pagani JL, Chave JP, Billie J. (1995). Transmission of oral C. albicans strains between HIV positive patients (letter). Lancet345:1052-1053.
20.
Borgers M., De Brabander M., Van den Bossche H., Van Cutsem J. (1979). Promotion of pseudomycelium formation of C. albicans in culture:a morphological study of the effects of miconazole and ketoconazole. Postgrad Med J55:687-691.
21.
Braga PC, Maci S., Dal-Sasso M., Bohn M. ( 1996). Experimental evidences for a role of subinhibitory concentrations of rilopirox, nystatin and fluconazole on adherence of Candida spp. to vaginal epithelial cells. Chemotherapy42:259-265.
22.
Brajtburg J., Elberg S., Medoff G., Kobayashi GS (1981). Increase in colony forming units of C. albicans after treatment with polyene antibiotics. Antimicrob Agents Chemother19:199-200.
23.
Brenciaglia MI, Ghezzi MC, Cipriani P., Mancini C., Trancassini M. (1986). The influence of antifungal drugs on adhesion of C. albicans to buccal epithelial cells. Chemotherapy5:200-203.
24.
Budtz-Jørgensen E. (1990). Candida-associated denture stomatitis and angular cheilitis. In: Oral candidosis. Samaranayake LP, MacFarlane TW, editors. London: Wright, pp. 156-183.
25.
Budtz-Jørgensen E., Stenderup A., Grabowski M. (1975). An epidemiological study of yeasts in elderly denture wearers. Community Dent Oral Epidemiol3:115-119.
26.
Cartledge ID, Midgley J., Gazzard BG (1997). Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidiasis. AIDS11:163-168.
27.
Chavanet P., Lopez J., Grappin M., Bonnin A., Duong M., Waldner A., et al. (1994). Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS8:945-950.
28.
Clark FS, Parkinson T., Hitchcock CA, Gow NA (1996). Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Antimicrob Agents Chemother40:419-425.
29.
Craig WA, Gudmundsson S. (1996). The postantibiotic effect. In: Antibiotics in laboratory medicine. Lorian V, editor. Baltimore: Williams & Wilkins, pp. 296-329.
30.
Dannaoui E., Colin S., Pichot J., Piens MA (1997). Evaluation of the E test for fluconazole susceptibility testing of C. albicans isolated from oropharyngeal candidiasis. Eur J Clin Microbiol Infect Dis16:228-232.
31.
Darwazeh AMG, Lamey PJ, Lewis MAO, Samaranayake LP (1991). Systemic fluconazole therapy and in vitro adhesion of C. albicans to human buccal epithelial cells. J Oral Pathol Med20:17-19.
32.
Darwazeh AMG, Lamey PJ, MacFarlane TW, McCuish AC (1994). The effect of exposure to chlorhexidine gluconate in vitro and in vivo on in vitro adhesion of C. albicans to buccal epithelial cells from diabetic and non-diabetic subjects. J Oral Pathol Med23:130-132.
33.
Darwazeh AMG, MacFarlane TW, Lamey PJ (1997). The in vitro adhesion of C. albicans to buccal epithelial cells from diabetic and non-diabetic individuals after in vivo and in vitro application of nystatin. J Oral Pathol Med26:233-236.
34.
Dewsnup DH, Stevens DA (1994). Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole. I Med Vet Mycol32:389-393.
35.
Dias AP, Samaranayake LP (1995). Clinical, microbiological and ultrastructural features of angular cheilitis lesions in Southern Chinese. Oral Dis1:43-48.
36.
Dias AP, Samaranayake LP, Lee MT (1997). Miconazole lacquer in the treatment of denture stomatitis: clinical and microbiological findings in Chinese patients. Clin Oral Invest1:47-52.
37.
Douglas WH, Walker DM (1973). Nystatin in denture liners; an alternative treatment of denture stomatitis. Br Dent J135:55-59.
38.
Dromer F., Improvisi L., Dupont B., Eliaszewicz M., Pialoux G., Fournier S., et al. (1997). Oral transmission of C. albicans between partners in HIV infected couples could contribute to dissemination of fluconazole-resistant isolates. AIDS11:1095-1101.
39.
Dupont B., Drouhet E. (1988). Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. J Med Vet Mycol26:67-71.
40.
Dupont BF, Dromer F., Improvisi L. (1996). The problem of azole resistance in Candida. J Mycol Med6:12-19.
41.
Eichel M., Just-Nubling G., Helm EB, Stille W. (1996). Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis. Mycoses39:102-106.
42.
Ellepola ANB, Samaranayake LP (1998a). The post antifungal effect (PAFE) of antimycotics on oral Candida albicans isolates and its impact on candidal adhesion. Oral Dis4:260-267.
43.
Ellepola ANB, Samaranayake LP (1998b). The effect of limited exposure to antifungal agents on the germ tube formation of oral Candida albicans. J Oral Pathol Med27:213-219.
44.
Ellepola ANB, Samaranayake LP (1998c). The effect of limited exposure to antimycotics on the relative cell-surface hydrophobicity and the adhesion of oral Candida albicans to buccal epithelial cells. Arch Oral Biol43:879-887.
45.
Ellepola ANB, Samaranayake LP (1998d). Adhesion of oral Candida albicans to human buccal epithelial cells following limited exposure to antifungal agents. J Oral Pathol Med27:325-332.
46.
Ellepola ANB, Samaranayake LP (1998e). Adhesion of oral Candida albicans isolates to denture acrylic following limited exposure to antifungal agents. Arch Oral Biol43:999-1007.
47.
Ellepola ANB, Samaranayake LP (1999a). In vitro postantifungal effect (PAFE) elicited by chlorhexidine gluconate on oral isolates of Candida albicans. Microb Ecol Health Dis11:143-148.
48.
Ellepola ANB, Samaranayake LP (1999b). The in vitro post antifungal effect of nystatin on Candida species of oral origin. I Oral Pathol Med28:112-116.
49.
Epstein I. (1990). Antifungal therapy in oropharyngeal mycotic infections. Oral Surg Oral Med Oral Pathol69:32-41.
50.
Ezsias A., Wojnarowska F., Juniper R. (1997). Topical use of miconazole antifungal oral gel on warfarinized patients: a word of caution. Dent Update (December):421-422.
51.
Feigal DW, Katz MH, Greenspan D. (1991). The prevalence of oral lesions in HIV-infected homosexuals and bisexual men: three San Francisco epidemiological cohorts. AIDS5:519-525.
52.
Fidel PL, Vazquez JA, Sobel JD (1999). Candida glabrata: review of epidemiology, pathogenesis, and clinical manifestations with comparison to Candida albicans. Clin Microbiol Rev12:80-96.
53.
Field EA, Millns B., Pearce PK, Martin MV, Parkinson T., Hitchcock CA (1996). Fluconazole therapy of oropharyngeal candidiasis in a patient with multiple endocrine failure does not correlate with C. albicans susceptibility to fluconazole in vitro. J Med Vet Mycol34:205-208.
54.
Finch RG, Snyder IS (1994). Antifungal drugs. In: Modern pharmacology. Craig CR, Stitzel RE, editors. Boston: Little, Brown, pp. 647-656.
55.
Flattery AM, Abruzzo GK, Gill CJ, Smith JG, Bartizal K. (1996) New model of oropharyngeal and gastrointestinal colonization by C. albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents. Antimicrob Agents Chemother40:1604-1609.
56.
Force RW, Nahata MC (1995). Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. Ann Pharmacother29:10-15.
57.
Franklin I., Elias E., Hirsch C. (1990). Fluconazole-induced jaundice. Lancet336:565.
58.
Fromtling RA (1984). Imidazoles as medically important antifungal agents: an overview. Drugs of Today20:325-349.
59.
Garber GE (1994). Treatment of oral Candida mucositis infections. Drugs47:734-740.
60.
Giuliana G., Pizzo G., Milici ME, Musotto GC, Giangreco R. (1997). In vitro antifungal properties of mouth rinses containing antimicrobial agents. J Periodontol68:729-733.
61.
Goff DA, Koletar SL, Buesching WJ, Barnisham J., Fass RJ ( 1995). Isolation of fluconazole-resistant C. albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin Infect Dis20:77-83.
62.
Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B., Kaizer H., et al. (1992). A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med326:845-851.
63.
Gombert ME, du Bouchet L., Aulicino TM, Butt KM ( 1987). A comparison of clotrimazole troches and oral nystatin suspension in recipients of renal transplants. J Am Med Assoc258:2553-2558.
64.
Graham BS, Jones DW, Burke J., Thompson JP (1991). In vivo presence and growth on two resilient denture liners. I Prosthet Dent65:528-532.
65.
Grbic JT, Mitchell-Lewis DA, Fine JB, Phelan JA, Bucklan RS, Zambon JJ, et al. (1995). The relationship of candidiasis to linear gingival erythema in HIV-infected homosexual men and parenteral drug users. I Periodontol66:30-37.
66.
Greenspan D. (1994). Treatment of oropharyngeal candidosis in HIV-positive patients. I Am Acad Dermatol31:S51-S55.
67.
Hanberger H., Svensson E., Nilsson M., Nilsson LE, Hornsten EG, Maller R. (1993). Effect of imipenem on Escherichia coli studied using bioluminescence, viable counting and microscopy. J Antimicrob Chemother31:245-260.
68.
Hawser SP, Douglas LJ (1995). Resistance of C. albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother39:2128-2131.
69.
Hay RJ (1990). Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis3:S334-S337.
70.
Heald AE, Cox GM, Schell WA, Bartlett JA, Perfect JR (1996). Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS10:263-268.
71.
Holmstrup P., Bessermann M. (1983). Clinical, therapeutic and pathogenic aspects of chronic oral multifocal candidiasis. Oral Surg Oral Med Oral Pathol56:388-395.
72.
lacopino A., Wathen W. (1992). Oral candidal infection and denture stomatitis: a comprehensive review. J Am Dent Assoc123:46-51.
73.
Johnson EM, Richardson MD, Warnock DW (1983). Effect of imidazole antifungals on the development of germ tubes by strains of C. albicans. J Antimicrob Chemother12:303-316.
74.
Johnson EM, Warnock DW, Luker J., Porter SR, Scully C. (1995). Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidiasis. J Antimicrob Chemother35:103-114.
75.
Kamalakshi BA, Santarpia PR, Pollack JJ, Renner RP (1992). Assessment of antimicrobial treatment of denture stomatitis using an in vivo replica model system: therapeutic efficacy of an oral rinse. I Prosthet Dent67:72-77.
76.
Kelly SL, Lamb DC, Kelly DE, Loeffler J., Einsele H. (1996). Resistance to fluconazole and amphotericin B in C. albicans from AIDS patients. Lancet348:1523-1524.
77.
Kirkpatrick CH (1993). Chronic mucocutaneous candidiasis. In: Candidiasis: pathogenesis, diagnosis and treatment. Bodey GP, editor. New York: Raven Press Limited, pp. 167-183.
78.
Klepser ME, Ernst EJ, Pfaller MA (1997). Update on antifungal resistance. Trends Microbiol5:372-375.
79.
Koletar SL, Russell JA, Fass RJ, Plouffe JF (1990). Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother34:2267-2268.
80.
Kolokotronis A., Kioses V., Antoniades D., Mandraveli K., Doutsos I., Papanayotou P. (1994). Immunologic status in patients infected with HIV and oral candidiasis and hairy leukoplakia and median rhomboid glossitis. An oral manifestation in patients infected with HIV. Oral Surg Oral Med Oral Pathol Oral Radiol Endod78:36-46.
81.
Konsberg R., Axéll T. (1994). Treatment of Candida-infected denture stomatitis with a miconazole lacquer. Oral Surg Oral Med Oral Pathol78:306-311.
82.
Kuc IM, Samaranayake LP, Van Heyst EN (1999). Oral health and microflora in an institutionalized elderly population in Canada. Int Dent J49:33-40.
83.
Kulak Y., Arikan A., Delibalta N. (1994). Comparison of three different treatment methods for generalized denture stomatitis. J Prosthet Dent72:283-288.
84.
Laguna F., Rodriguez-Tudela JL, Martinez-Suarez RP, Valencia E., Diaz-Guerra TM, Dronda F., et al. (1997). Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Clin Infect Dis24:124-130.
85.
Lamb DC, Kelly DE, Schunck WH, Shyadehi AZ, Akhtar M., Lowe DJ, et al. (1997). The mutation T315A in C. albicans sterol 14 alpha demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem272:5682-5688.
Lamey P.J., Lewis MAO, MacDonald G. (1989). Treatment of candidal leukoplakia with fluconazole. Br Dent J166:296-298.
88.
Laufen H., Yeates RA, Zimmermann T., de Los Reyes C. (1995). Pharmacokinetic optimization of the treatment of oral candidiasis with fluconazole: studies with a suspension. Drugs Exp Clin ResXXI:23-28.
89.
Laurence DR, Bennett PN, Brown MJ (1997). Chemotherapy of fungal infections. In: Clinical pharmacology. Laurence DR, Bennett PN, Brown MI, editors. UK: Churchill Livingstone, pp. 235-238.
90.
Le TP, Tuazon CU, Levine M., Borum M., Rollhauser C. (1996). Resistance to fluconazole and amphotericin B in a patient with AIDS who was being treated for candidal esophagitis. Clin Infect Dis23:649-650.
91.
Le Guennec R., Reynes J., Mallie M., Pujol C., Janbon F., Bastide JM (1995). Fluconazole and itraconazole-resistant C. albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities. J Clin Microbiol33:2732-2737.
92.
Lesse AJ (1995). Antifungal agents. In: Essentials of pharmacology. Smith CM, Reynard A, editors. Philadelphia: W.B. Saunders, pp. 404-411.
93.
Lilic D., Cant AJ, Abinun M., Calvert JE, Spickett GP (1996). Chronic mucocutaneous candidiasis: 1. Altered antigen-stimulated IL-2, IL-4, IL-6 and interferon-gamma (IFN-γ) production. Chronic mucocutaneous candidiasis: II. Class and subclass of specific antibody responses in vivo and in vitro. Clin Exp Immunol105:205-219.
94.
Lortholary O., Dupont B. (1997). Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev10:477-504.
95.
Lucatorto FM, Franker C., Hardy WD, Chafey S. (1991). Treatment of refractory oral candidiasis with fluconazole. A case report. Oral Surg Oral Med Oral Pathol71:42-44.
96.
MacPhail LA, Hilton JF, Dodd CL, Greenspan D. (1996). Prophylaxis with nystatin pastilles for HIV-associated oral candidiasis. J Acquir Immune Defic Syndr Hum Retrovirol12:470-476.
97.
Macura AB (1988). The influence of some antifungal drugs on in vitro adherence of C. albicans to human buccal epithelial cells. Mycoses31:71-76.
98.
Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE (1996). Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus infected patients. J Infect Dis173:219-225.
99.
Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE (1997). Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis24:28-34.
100.
Marichal P., Vanden-Bossche H., Odds FC, Nobels G., Warnock DW, Timmerman V., et al. (1997). Molecular biological characterization of an azole-resistant C. glabrata isolate. Antimicrob Agents Chemother41:2229-2237.
101.
Martin MV (1989). A comparison of fluconazole and ketoconazole in the treatment of rat palatal candidosis. J Med Vet Mycol27:63-70.
102.
Martin MV (1990). Antifungal agents. In: Oral candidosis. Samaranayake LP, MacFarlane TW, editors. London: Wright, pp. 238-255.
103.
Martin MV, Farrelley PJ, Hardy P. (1986). An investigation of the efficiency of nystatin for the treatment of chronic atrophic candidosis (denture sore mouth). Br Dent J160:201-204.
104.
Martinez MA, Gutierrez MJ, Aller AI, Montero O., Morilla D., Bernal S., et al. (1997). In vitro susceptibility of itraconazole against fluconazole resistant and susceptible Candida spp. isolated from oral cavities of HIV infected patients. J Mycol Med7:123-127.
105.
Martins MD, Rex JH (1997). Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets. Ann Intern Med126:332-333.
106.
Mathaba LT, Davies G., Warmington JR (1995). The genotypic relationship of C. albicans strains isolated from the oral cavity of patients with denture stomatitis. J Med Microbiol42:372-379.
107.
McCourtie J., MacFarlane TW, Samaranayake LP (1985). Effect of chlorhexidine gluconate on the adherence of Candida species to denture acrylic. J Med Microbiol20:97-104.
108.
McCourtie J., MacFarlane TW, Samaranayake LP (1986). A comparison of the effects of chlorhexidine gluconate, amphotericin B and nystatin on the adherence of Candida species to denture acrylic. J Antimicrob Chemother17:575-583.
109.
McGinnis MR, Rinaldi MG (1996). Antifungal drugs: mechanisms of action, drug resistance, susceptibility testing and assays of activity in biological fluids. In: Antibiotics in laboratory medicine. Lorian V, editor. Baltimore: Williams & Wilkins, pp. 176-211.
110.
Millns B., Martin MV (1996). Nystatin pastilles and suspension in the treatment of oral candidosis. Br Dent J181:209-211.
111.
Minguez F., Chiu ML, Lima JE, Nique R., Prieto J. (1994). Activity of fluconazole: postantibiotic effect, effects of low concentrations and of pretreatment on the susceptibility of C. albicans to leukocytes. J Antimicrob Chemother34:93-100.
112.
Napier SS, MacDonald DG, Lamey PJ (1996). Cheilocandidosis in an adult. Br Dent J181:336-338.
113.
National Committee for Clinical Laboratory Standards (1995). Reference method for broth dilution antifungal susceptibility testing of yeasts: tentative standards. NCCLS document M27-T. Villanova, PA: NCCLS.
114.
Newton AV (1962). Denture sore mouth: a possible aetiology. Br Dent J112:357-360.
115.
Ng TT, Denning DW (1993). Fluconazole resistance in Candida in patients with AIDS: a therapeutic approach. J Infect26:117-125.
116.
Nguyen MT, Weiss PJ, LaBarre RC, Miller LK, Oldfield EC, Wallace MR (1996). Orally administered amphotericin B in the treatment of oral candidiasis in HIV-infected patients caused by azole-resistant C. albicans. AIDS10:1745-1747.
117.
Nikawa H., Samaranayake LP, Tenovuo J., Hamada T. (1994). The effect of antifungal agents on the in vitro susceptibility of C. albicans to apo-lactoferrin. Arch Oral Biol39:921-923.
118.
Ninane J., Gluckman E., Hann I., Gibson BS, Stevens RF (1994). A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Eur J Clin Microbiol Infect Dis13:330-337.
119.
Odden K., Schenck K., Koppang HS, Hurlen B. (1994). Candidal infection of the gingiva in HIV-infected persons. J Oral Pathol Med23:178-183.
120.
Odds FC ( 1994). Candida and candidosis. A review and bibliography. London: Ballière, Tindall.
121.
Odds FC, Webster CE (1988). Effect of azole antifungals in vitro on host parasite interactions relevant to Candida infections. J Antimicrob Chemother2:473-481.
122.
Odman PA (1992). The effectiveness of an enzyme-containing denture cleanser. Quint Int23:187-190.
123.
Ohtsuka K., Watanabe M., Orikasa Y., Inouye S., Uchida K., Yamaguchi H., et al. (1997). The in vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole. J Antimicrob Chemother39:71-77.
124.
Okita N., Orstavik D., Orstavik J., Ostby K. (1991). In vivo and in vitro studies on soft denture materials: microbial adhesion and tests for antibacterial activity. Dent Mater7:155-160.
Pfaller MA (1996). Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis22:S89-S94.
127.
Pfaller MA, Rex JH, Rinaldi MG (1997). Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis24:776-784.
128.
Phillips P., Zemcov I., Mahmood W., Montaner JSG, Craib K., Clarke AM (1996). Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS10:1369-1376.
129.
Pons V., Greenspan D., Debriun M. (1993). Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. I Acquir Immune Defic Syndr6:1311-1316.
130.
Pons V., Greenspan D., Lozada-Nur F., McPhail L., Gallant JE, Tunkel A., et al. (1997). Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis24:1204-1207.
Quinn DM (1985). The in vitro effectiveness of miconazole and ketoconazole combined with tissue conditioners in inhibiting the growth of Candida albicans. J Oral Rehabil12:177-182.
133.
Ramadan MA, Tawfik AF, Shibl AM, Gemmell CG (1995). Post-antibiotic effect of azithromycin and erythromycin on streptococcal susceptibility to phagocytosis. J Med Microbiol42:362-366.
134.
Ramani R., Ramani A., Wong SJ ( 1997). Rapid flow cytometric susceptibility testing of C. albicans. J Clin Microbiol35:2320-2324.
135.
Reichart PA, Schmidt-Westhausen A., Samaranayake LP, Philipsen HP (1994). Candida-associated palatal papillary hyperplasia in HIV infection. J Oral Pathol Med23:403-405.
136.
Reichart PA, Weigel D., Schmidt-Westhausen A., Pohle HD (1997). Exfoliative cheilitis (EC) in AIDS: association with Candida infection. J Oral Pathol Med26:290-293.
137.
Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, et al. (1996). Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis174:821-827.
138.
Rex JH, Rinaldi MG, Pfaller MA (1995a). Resistance of Candida species to fluconazole. Antimicrob Agents Chemother39:1-8.
139.
Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD ( 1995b). Antifungal susceptibility testing of isolates from a randomized multi-center trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrob Agents Chemother39:40-44.
140.
Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A., Ghannoum MA, et al. (1997). Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections. Clin Infect Dis24:235-247.
141.
Ruhnke M., Eigler A., Tennagen I., Geiseler B., Engelmann E., Trautmann M. (1994). Emergence of fluconazole resistant strains of C. albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol32:2092-2098.
142.
Ruhnke M., Schmidt-Westhausen A., Trautmann M. (1997). In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and resistant C. albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother41:575-577.
143.
Samaranayake LP (1990). Host factors and oral candidosis. In: Oral candidosis. Samaranayake LP, MacFarlane TW, editors. London: Wright, pp. 66-103.
Samaranayake LP, MacFarlane TW (1981). A retrospective study of patients with recurrent chronic atrophic candidosis. Oral Surg Oral Med Oral Pathol52:150-153.
Samaranayake YH, Samaranayake LP (1994). C. krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. J Med Microbiol41:295-310.
154.
Sangeorzan JA, Bradley SF, He X., Zarins LT, Ridenour GL, Tiballi RN, et al. (1994). Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment and emergency of fluconazole resistance. Am J Med97:339-346.
155.
Sanglard D., Kuchler K., Ischer F., Pagani J.-L, Monod M., Bille J. (1995). Mechanisms of resistance to azole antifungal agents in C. albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother39:2378-2386.
156.
Scalarone GM, Mikami Y., Kurita N., Yazawa K., Uno J., Miyaji M. (1991). In vitro comparative evaluations of the postantifungal effect: synergistic interaction between flucytosine and fluconazole against C. albicans. Mycoses34:405-410.
157.
Scalarone GM, Mikami Y., Kurita N., Yazawa K., Miyaji M. (1992). The postantifungal effect of 5-fluorocytosine on C. albicans. J Antimicrob Chemother29:129-136.
158.
Scheutz F., Matee MI, Simon E., Mwinula JH, Lyamuya EF, Msengi AE, et al. (1997). Association between carriage of oral yeasts, malnutrition and HIV-infection among Tanzanian children aged 18 months to 5 years. Community Dent Oral Epidemiol25:193-198.
159.
Schneid TR (1992). An in vitro analysis of a sustained release system for the treatment of denture stomatitis. Spec Care Dent12:245-250.
160.
Schuman P., Capps L., Peng G., Vazquez J., el-Sadr W., Goldman AI, et al. (1997). Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med126:689-696.
161.
Scully C., El-Kabir M., Samaranayake LP (1994). Candida and oral candidosis: a review. Crit Rev Oral Biol Med5:125-157.
162.
Scully C., Almeida ODP, Sposto MR (1997). The deep mycoses in HIV infection. Oral Dis3:S200-S207.
163.
Sedgley CM, Samaranayake LP, Chan ICY, Wei SHY (1997). A 4 year longitudinal study of the oral prevalence of enteric Gram-negative rods and yeasts in Chinese children. Oral Microbiol Immunol12:183-188.
164.
Shaoxi W., Ningru G., Youhong H. (1996). Effects of systemic fluconazole therapy on in vitro adhesion of C. albicans to buccal epithelial cells and changes of the cell surface proteins of the epithelial cells. Chinese Med Sci J11:45-48.
165.
Sheehan DJ, Hitchcock CA, Sibley CM (1999). Current and emerging azole antifungal agents. Clin Microbiol Rev12:40-79.
166.
Shibl AM, Ramadan MA, Tawfik AF (1994). Post-antibiotic effect of roxithromycin on streptolysin 0 production, hydrophobicity and bactericidal activity of PMNL by Streptococcus pyogenes. Diagn Microbiol Infect Dis20:7-11.
167.
Shibl AM, Pechere JC, Ramadan MA (1995). Postantibiotic effect and host-bacteria interactions. J Antimicrob Chemother36:885-887.
168.
Siegman-Igra Y., Raban MY (1992). Failure of fluconazole in systemic candidiasis. Eur J Clin Microbiol Infect Dis11:201-202.
169.
Silverman S., Gallo JW, McKnight ML, Mayer P., deSanz S., Tan MM (1996). Clinical characteristics and management responses in 85 HIV-infected patients with oral candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod82:402-407.
170.
Smith DE, Midgley J., Allan M., Connolly GM, Gazzard BG (1988). Itraconazole versus ketoconazole in the treatment of oral and esophageal candidosis in patients infected with HIV. AIDS5:1367-1371.
171.
Soames JV, Southam JC (1993). Infections of the oral mucosa. In: Oral pathology. Soames IV, Southam JC, editors. New York: Oxford, pp. 185-191.
172.
Sobel JD, Obedeanu N. (1983). Effects of subinhibitory concentrations of ketoconazole on in vitro adherence of C. albicans to vaginal epithelial cells. Eur J Clin Microbiol2:445-452.
173.
Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC (1995). Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiol141:1507-1521.
174.
Thomas CJ, Nutt GM ( 1978). The in vitro fungicidal properties of Visco-gel, alone and combined with nystatin and amphotericin B. J Oral Rehabil5:167-172.
175.
Tobgi RS, Samaranayake LP, MacFarlane TW (1987). Adhesion of C. albicans to buccal epithelial cells exposed to chlorhexidine gluconate. J Med Vet Mycol25:335-338.
176.
Troke PFK, Marriott MS, Richardson J. (1988). In vitro potency and in vivo activity of azoles. Ann NY Acad Sci544:284-293.
177.
Tumbarello M., Tacconelli E., Caldarola G., Morace G., Cauda R., Ortona L. (1997). Fluconazole resistant oral candidiasis in HIV-infected patients. Oral Dis3:S110-S112.
178.
Turnidge JD, Gudmundsson S., Vogelman B., Craig WA (1994). The postantibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother34:83-92.
179.
Van Cutsem J. (1994). Prophylaxis of Candida and Aspergillus infections with oral administration of itraconazole. Mycoses37:243-248.
180.
Van't Wout JW (1996). Fluconazole treatment of candidal infections caused by non-albicans Candida species. Eur J Clin Microbiol Infect Dis15:238-243
181.
Varthalitis I., Meunier F. (1995). Prophylaxis of fungal infections. In: Bailliere's clinical infectious diseases. Meunier F, editor. London: Baillière, Tindall, pp. 157-177.
182.
Vuddhakul V., McCormack JG, Seow WK, Smith SE, Thong YH (1988). Inhibition of adherence of C. albicans by conventional and experimental antifungal drugs. I Antimicrob Chemother21:755-763.
183.
Walker DM, Arendorf T. (1990). Candidal leucoplakia, chronic multifocal candidosis and median rhomboid glossitis. In: Oral candidosis. Samaranayake LP, MacFarlane TW, editors. London: Wright, pp. 184-199.
184.
Warnakulasuriya KAAS, Samaranayake LP, Peiris JSM (1991). Angular cheilitis in a group of Sri Lankan adults. J Oral Pathol Med20:172-175.
185.
Warnock DW (1991). Amphotericin B: an introduction. J Antimicrob Chemother28:27-38.
Wells C., Lever AM (1992). Dose dependent fluconazole hepatotoxicity proven on biopsy and re-challenge. J Infect24:111-112.
188.
Wheat LJ (1993). Diagnosis and management of fungal infections in AIDS. Curr Opin Infect Dis6:617-627.
189.
White TC, Pfaller MA, Rinaldi MG, Smith J., Redding SW (1997). Stable azole drug resistance associated with a substrain of C. albicans from an HIV-infected patient. Oral Dis3:S102-S109.
190.
White TC, Marr KA, Bowden RA (1998). Clinical, cellular and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev11:382-402.
191.
Wildfeuer A., Laufen H., Yeates RA, Zimmermann T. (1996). A new pharmaceutical concept for the treatment of oropharyngeal and oesophageal candidosis with fluconazole. Mycoses39:357-360.
192.
Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber IL, Horowitz H., et al. (1993). Fluconazole prophylaxis of fungal infection in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med118:495-503.
193.
Wu T., Samaranayake LP, Cao BY, Wang J. ( 1996). In vitro proteinase production by oral C. albicans isolates from individuals with and without HIV infection and its attenuation by antimycotic agents. Med Microbiol44:311-316.
194.
Zegarelli DJ (1993). Fungal infections of the oral cavity. Otolaryngol Clin North Am26:1069-1089.
195.
Zhanel GG, Hoban DJ, Harding KM (1991). The postantibiotic effect: a review of in vitro and in vivo data. DICP Ann Pharmacother25:153-163.
